Krämer, Oliver H.

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal

Histone Deacetylase Inhibitors ResearchUbiquitin and proteasome pathways

Cited by 523

HDAC2: a critical factor in health and disease

Krämer, O. H. (2009) · Trends in Pharmacological Sciences

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 157

Cross talk between stimulated NF-κB and the tumor suppressor p53

Schneider, G., Henrich, A., Greiner, G., Wolf, V, Lovas, A., Wieczorek, M., Wagner, T., Reichardt, S., von Werder, A., Schmid, R. M., et al. (2010) · Oncogene

NF-κB Signaling PathwaysCancer-related Molecular Pathways

Cited by 149

Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance

Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research

Histone Deacetylase Inhibitors ResearchDNA Repair Mechanisms

Cited by 91

NFκB/p53 crosstalk—a promising new therapeutic target

Schneider, G., & Krämer, O. H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

NF-κB Signaling PathwaysCancer-related Molecular Pathways

Cited by 87

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

Toutah, K., Nawar, N., Timonen, S., Sorger, H., Raouf, Y. S., Bukhari, S., von Jan, J., Ianevski, A., Gawel, J. M., Olaoye, O. O., et al. (2021) · Journal of Medicinal Chemistry

Histone Deacetylase Inhibitors ResearchChronic Lymphocytic Leukemia Research

Cited by 51

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity

Ibrahim, H. S., Abdelsalam, M., Zeyn, Y., Zessin, M., Mustafa, A.-H. M., Fischer, M. A., Zeyen, P., Sun, P., Bülbül, E. F., Vecchio, A., et al. (2021) · International Journal of Molecular Sciences

Histone Deacetylase Inhibitors ResearchHeterocyclic Compound Synthesis and Bioactivity

Cited by 50

Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death

Conradt, L., Henrich, A., Wirth, M., Reichert, M., Lesina, M., Algül, H., Schmid, R. M., Krämer, O. H., Saur, D., & Schneider, G. (2013) · International Journal of Cancer

Cancer-related Molecular PathwaysPancreatic and Hepatic Oncology Research

Cited by 30

Free enthalpies of replacing water molecules in protein binding pockets.

Riniker, S., Barandun, L. J., Diederich, F., Krämer, O., Steffen, A., & van Gunsteren, W. F. (2012) · Journal of Computer-Aided Molecular Design

Computational Drug Discovery MethodsProtein Structure and Dynamics

Cited by 23

Medicinal chemistry advances in targeting class I histone deacetylases

Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy

Histone Deacetylase Inhibitors ResearchEnzyme function and inhibition

Cited by 17